• Journal of Microbiology and Biotechnology
• /
• 제18권4호
• /
• pp.788-794
• /
• 2008

The aim of the present study is to estimate the overall prevalence and type distribution of human papillomavirus (HPV) in Korean women, through literature review and meta-analysis. We searched published data for the period between 1995 and 2007 using the following inclusion criteria; (1) studies using type-specific HPV tests, (2) data from Korean female, (3) with cytologic or pathologic results, (4) having more than 20 cases for each subgroup classified by cytologic results, and (5) HPV detection including types 16, 18, and at least one other type. In total, 18 studies (13,842 cases) published up to April 2007 were identified and selected. Adjusted overall HPV prevalence was 23.9% (95% CI: 23.8-24.1%) in women with normal cytology and 95.8% (95% CI: 95.4-96.2%) in women with cervical cancer. Type 16 was predominant regardless of cervical disease status, and type 58 occupied a significantly larger proportion in high-grade cervical intraepitheliallesions and cervical cancer in Korean women. HPV types 58, 33, and 52 together accounted for about 20% of infections in cervical cancer and high-grade intraepitheliallesions. After introduction of HPV prophylactic vaccines, extended protection, especially against types 58, 33, and 52, will be an important issue for cervical cancer prevention in Korea. The future dominant genotypes will require follow-up epidemiological studies with a large-scale, multicentered, and prospective design.

• 한국임상약학회지
• /
• 제30권1호
• /
• pp.19-30
• /
• 2020

Objective: To describe patterns of spontaneous reporting on adverse events following immunization (AEFIs) using the human papilloma virus (HPV) vaccine according to the Brighton Collaboration (BC) criteria. Methods: We used the Korea Adverse Event Reporting System (KAERS) database including vaccinations between 2008 and 2017. To apply BC criteria, we classified 58 BC AEFIs into World Health Organization Adverse Reaction Terminology (WHO-ART) codes. We applied MedDRA standard medical queries that were pre-defined as five BC AEFIs. Terminology mapping between MedDRA and WHO-ART terms was performed by three researchers. Descriptive statistics of individual case safety reports were analyzed according to BC applicability. Disproportionality analyses were performed on each BC AEFI and each preferred AEFI term according to the case-noncase approach; reporting odds ratio (ROR) and 95% confidence intervals (CI) were calculated. Results: Among the 30,266 reports of vaccinations between 2008 and 2017, 2,845 reports included the HPV vaccine. Of these reports, 1,511 (53.1%) included at least one BC AEFI. Reports from physicians or manufacturers included more BC AEFIs than from other reporters. Injection site reactions and fever were frequently reported in BC AEFIs; spontaneous abortion and ectopic pregnancy (ROR, 14.29 [95% CI, 4.30-47.49]) and vasculitic peripheral neuropathy (ROR, 8.57 [95% CI, 2.61-28.10]) showed the highest ROR. Among non-BC AEFIs, dizziness or myalgia were frequently reported; exposure during pregnancy (ROR, 23.95 [95% CI, 16.27-35.25]) and inappropriate schedule of administration (ROR, 22.89 [95% CI, 16.74-31.31]) showed the highest ROR. Conclusion: BC criteria would be applicable for labeled AEFIs, whereas analyzing non-BC AEFIs would be useful for detecting unlabeled AEFIs.

• 대한의생명과학회지
• /
• 제22권2호
• /
• pp.37-45
• /
• 2016

High risk human papillomavirus (HR-HPV) is major risk factor for uterine cervical cancer. There are approximately 15 types of HR-HPV. Liquid based cytology samples (116 samples) with high grade cervical lesions belonging to cervical intraepithelial neoplasia (CIN) 2, CIN 3, carcinoma in situ (CIS) and squamous cell carcinoma (SCC) were used after histologic confirmation. HR-HPV genotype assay was conducted using DNA chips. The HR-HPV infection rate was 81.9% with SCC samples showing the highest HR-HPV infection rate of 31%. CIN 3, CIS and CIN 2 showed infection rates of 25%, 16.4% and 9.5%, respectively. According to age with HR HPV infection rate, the 30~39 years-old group showed the highest infection rate by 92.3%. According to distribution with HR HPV genotyping, HPV 16 showed the highest infection rate by 42.3% whereas HPV 33 and HPV 58 showed infection rates of 11.7% and 10.8%, respectively. HPV 18 which is the second most common infected HPV genotype in the world showed 3.6%. Of the three most common oncogenic HR-HPV genotypes in CIN 2, we detected HPV 16, 35, 58; CIN 3 was HPV 16, 33, 58; CIS was HPV 16, 58, 33 (35/52); and SCC was HPV 16, 33, and 18 (31/52/58). Among the HPV 18, CIN 2, CIN 3, CIS and SCC showed 0.9%, 0.9%, 0% and 1.8%, respectively. The most often used preventive vaccines for cervical cancers use HPV 16 and HPV 18 as targets. However, results derived from this study suggest that a preventive vaccine against HPV 16 and HPV 18 would not be optimal for populations in this study.

• IMMUNE NETWORK
• /
• 제5권2호
• /
• pp.89-98
• /
• 2005

Background: DNA vaccination represents an anticipated approach for the control of numerous infectious diseases. Used alone, however, DNA vaccine is weak immunogen inferior to viral vectors. In recent, heterologous prime-boost vaccination leads DNA vaccines to practical reality. Methods: We assessed prime-boost immunization strategies with a DNA vaccine (minigene, $gB_{498-505}$ DNA) and recombinant vaccinia virus $(vvgB_{498-505})$ expressing epitope $gB_{498-505}$ (SSIEF ARL) of CD8+ T cells specific for glycoprotein B (gB) of herpes simplex virus (HSV). Animals were immunized primarily with $gB_{498-505}$ epitope-expressing DNA vaccine/recombinant vaccinia virus and boosted with alternative vaccine type expressing entire Ag. Results: In prime-boost protocols using vvgBw (recombinant vaccinia virus expressing entire Ag) and $vvgB_{498-505}$, CD8+ T cell-mediated immunity was induced maximally at both acute and memory stages if primed with vvgBw and boosted with $vvgB_{498-505}$ as evaluated by CTL activity, intracellular IFN-staining, and MHC class I tetramer staining. Similarly $gB_{498-505}$ DNA prime-gBw DNA (DNA vaccine expressing entire Ag) boost immunization elicited the strongest CD8+ T cell responses in protocols based on DNA vaccine. However, the level of CD8+ T cell-mediated immunity induced with prime-boost vaccination using DNA vaccine expressing epitope or entire Ag was inferior to those based on vvgBw and $vvgB_{498-505}$. Of particular interest CD8+ T cell-mediated immunity was optimally induced when $vvgB_{498-505}$ was used to prime and gB DNA was used as alternative boost. Especially CD7+ T cell responses induced by such protocol was longer lasted than other protocols. Conclusion: These facts direct to search for the effective strategy to induce optimal CD8+ T cell-mediated immunity against cancer and viral infection.

• 공업화학
• /
• 제28권4호
• /
• pp.404-409
• /
• 2017

천연고분자 키토산은 생체적합하고 생분해성의 특성뿐만 아니라 항암, 항균, 콜레스테롤 저하 등의 다양한 생체활성을 갖고 있어 의료용 분야에서 많이 응용되고 있다. 현재 키토산을 약물전달시스템에 응용한 다양한 약물이 담지 된 키토산 나노입자를 개발하여 질병을 치료할 수 있는 연구가 활발히 진행 중에 있다. 키토산에 존재하는 free 아민($-NH_2$) 그룹은 다양한 소수성기를 물리적 화학적 개질을 통해 결합이 가능하며 소수성기가 도입된 키토산은 물에 분산시 자기회합에 의한 shell-core 나노입자를 형성하고 core 부분에 다양한 난용성 약물을 담지하여 물에 대한 용해도를 증가시킬 수 있으며, 단백질, 항암제, 백신 등의 다양한 약물을 담지하여 기존 약물의 부작용을 최소화하여 치료효과를 극대화할 수 있다. 또한, 키토산에 도입된 소수성기에 따라 입자의 크기 및 방출 속도를 제어할 수 있어 다양한 의료용 분야에 응용이 가능하다. 본 총설에서는 다양한 소수성기가 도입된 키토산 나노입자의 제조 및 특성과 특성에 따른 약물전달시스템의 응용성에 관하여 논의 하고자 한다.

• 대한임상검사과학회지
• /
• 제48권3호
• /
• pp.247-254
• /
• 2016

인간 유두종 바이러스(HPV)에 의한 감염은 자궁경부암의 원인이다. HPV DNA의 세포 검사에서의 변화는 향후 더 도전적으로 발전을 기대한다, HPV 유전자형의 감염에 대한 새로운 HPV의 DNA(22종) chip 검사는 최근 한국에서 많이 개발되었다. 이 연구의 목적은 서울 지역에서 HPV 감염의 빈도와 유전자형 분포를 알아보고자 하였다. 지난 2015년 한 해 동안 서울지역 종합병원 내원객을 대상으로 총 5,614 검체의 검사에서 HPV 유전자형은 1,596 (28.4%)에서 검출되었다, 이중 한 종류의 유전자형은 가진 검체(n=831) 중고위험 HPV는 679 (42.5%), 저위험 HPV는 152 (9.5%)로 나타났다. 이중 자주 발견 유전자형은 HPV-16 (16.5%), 58 (15.2%), 52(8.8%), 51 (7.1%), 56 (5.9%) 순이었다. 혼합 유전자형(n=219) 중 2종(n=176, 11.0%), 3종(n=37, 5.9%), 4종(n=2, 0.1%)이 나타났다 이에 본 연구는 종합 병원 방문자의 HPV 감염을 조사하였다. 이러한 연구 결과는 HPV 전국적으로 분포 및 백신의 도입을 안내하는 데 이용될 수 있을 것으로 사료되며 진료에 중요한 정보를 제공하며 역학적 추가 연구가 요구된다.

• Journal of Preventive Medicine and Public Health
• /
• 제43권2호
• /
• pp.109-116
• /
• 2010

Objectives: The pandemic of novel influenza A (H1N1) virus has required decision-makers to act in the face of the substantial uncertainties. In this study, we evaluated the potential impact of the pandemic response strategies in the Republic of Korea using a mathematical model. Methods: We developed a deterministic model of a pandemic (H1N1) 2009 in a structured population using the demographic data from the Korean population and the epidemiological feature of the pandemic (H1N1) 2009. To estimate the parameter values for the deterministic model, we used the available data from the previous studies on pandemic influenza. The pandemic response strategies of the Republic of Korea for novel influenza A (H1N1) virus such as school closure, mass vaccination (70% of population in 30 days), and a policy for anti-viral drug (treatment or prophylaxis) were applied to the deterministic model. Results: The effect of two-week school closure on the attack rate was low regardless of the timing of the intervention. The earlier vaccination showed the effect of greater delays in reaching the peak of outbreaks. When it was no vaccination, vaccination at initiation of outbreak, vaccination 90 days after the initiation of outbreak and vaccination at the epidemic peak point, the total number of clinical cases for 400 days were 20.8 million, 4.4 million, 4.7 million and 12.6 million, respectively. The pandemic response strategies of the Republic of Korea delayed the peak of outbreaks (about 40 days) and decreased the number of cumulative clinical cases (8 million). Conclusions: Rapid vaccination was the most important factor to control the spread of pandemic influenza, and the response strategies of the Republic of Korea were shown to delay the spread of pandemic influenza in this deterministic model.

• Parasites, Hosts and Diseases
• /
• 제54권3호
• /
• pp.301-305
• /
• 2016

In order to determine the effect of various hosts on feeding performance of Rhipicephalus (Boophilus) microplus, we used 3 mammalian species as hosts, cattle (Qinchuan), sheep (Tan), and rabbits (Japanese white rabbit) for infesting ticks. Five hundreds of R. microplus larvae were exposed to each animal (3 animals/host species). Tick recoveries were 11.0%, 0.47%, and 5.5% from cattle, sheep, and rabbits, respectively. The averages of tick feeding periods were not significantly different on cattle, sheep, and rabbits, 28.8, 25.3, and 26.7 days, respectively. The average weights of individual engorged female from cattle, sheep, and rabbits were 312.5, 219.1, and 130.2 mg, respectively and those of egg mass weights each to 85.0, 96.6, and 17.8 mg. The highest egg hatching rate was in the ticks from cattle (96.0%), followed by those from rabbits (83.0%) and sheep (19.2%). These data suggest that rabbits could be as an alternative host to cultivate R. microplus for evaluating vaccines and chemical and biological medicines against the tick in the laboratory, although the biological parameters of ticks were less than those from cattle.

• Pediatric Infection and Vaccine
• /
• 제21권3호
• /
• pp.167-173
• /
• 2014

목적: 최근 로타바이러스 백신의 효과 및 안정성에 대한 연구 결과를 바탕으로 전세계적으로 접종이 시행이 되고 있다. 국내에도 로타바이러스 백신 도입 후 5년이 경과되었지만 백신효과에 대한 국내 자료가 매우 드문 실정이다. 로타바이러스 백신 도입을 전후하여 급성위장관염 및 로타바이러스 위장관염 환자의 발생 추이를 알아보고자 하였다. 방법: 2005-2006년, 2011-2012년의 인제대학교 상계백병원 소아청소년과 실입원환자수를 조사하였으며 같은 기간동안 급성위장관염으로 진단되어 인제대학교 상계백병원에 입원한 5세 미만 소아환자 2,840명의 의무기록을 후향적으로 분석하였다. 2005-2006년을 백신 도입 이전, 2011-2012년을 백신 도입 이후로 분류하여 5세 미만 소아 연령에서 급성위장관염 환자와 대변 로타항원 검사 결과로 확인된 로타바이러스 급성위장관염 환자의 입원 양상의 변화를 파악하였다. 결과: 로타바이러스 백신 도입 이전군(2005-2006년)에 비해 이후군(2011-2012년)에서 급성위장관염으로 입원한 5세 미만 환자는 생후 2개월 미만 군을 제외한 모든 월령군에서 유의한 환자수의 감소를 보였다. 로타바이러스 급성위장관염 환자는 생후 2개월 미만 군과 생후 2-5개월 월령군을 제외한 월령군에서 유의한 환자수의 감소를 보였다. 결론: 로타바이러스 백신이 국내에 도입된 이후에 도입 이전에 비해 생후 6-59개월군의 급성위장관염 입원 환자에서 로타바이러스 위장관염이 감소하였다. 향후에도 로타바이러스 백신의 효과 및 안정성에 대한 지속적인 관심과 연구가 필요할 것으로 보인다.

• 대한수의학회지
• /
• 제40권3호
• /
• pp.533-541
• /
• 2000

Biochemical and genetic analysis were carried out to investigate the potential recovery of pathogenecity or related mutations of Brucella abortus RB51 vaccine strains. RB51 strains were recovered from commercial vaccines, including related seed stocks from private companies in Republic of Korea, strain from USA, a reference strain from C university and a field isolate (Daehungjin) from aborted dairy cow after RB51 vaccination were compared with two identified virulent wild strains (S2308 and a field strain isolated from dairy cow in Korea) at the same conditions. All the strains examined, except identified pathogenic strains, revealed the identical characteristics to the original RB51 in biochemical properties, antigen and bacteriophage typing. Outer membrane protein (OMP) profiles from strains of RB51 showed the same patterns with standard RB51 in SDS-PAGE. In addition, Western blotting with the brucella specific monoclonal antibody also indicated that all the vaccine strains were completely deficient in their LPS compared to the pathogenic Br abortus strains. The differences in DNA structures among strains were also possible to detect after PCR. All vaccine strains, except S19, S1119-3, S1075, S544 and Br suis, were amplified a 178bp DNA fragment of eri-gene, and 364bp of IS711 elements. In contrast, 498bp DNA product was only found with Br abortus. Overall evidences in the present study confirmed that the RB51 strains for vaccine production in Korea did not originated from the phenomena of possible recovery of pathogenicity or related to any potential mutation event at all.